3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
ribociclib
×
Clear all
No trials found.